Ticker > Company >

Biocon share price

Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  280k   1k   273

355.45
0 0
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 357.6

Today's Low

₹ 345.25

52 Week High

₹ 404.6

52 Week Low

₹ 290.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

42675.33 Cr.

Enterprise Value

44130.43 Cr.

No. of Shares

120.06 Cr.

P/E

70.04

P/B

3.7

Face Value

₹ 5

Div. Yield

0.14 %

Book Value (TTM)

₹  95.99

CASH

585.7 Cr.

DEBT

2040.8 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  5.08

Sales Growth

6.74%

ROE

1.1 %

ROCE

2.77%

Profit Growth

-95.81 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year6.74%
3 Year1.6%
5 Year3.56%

Profit Growth

1 Year-95.81%
3 Year-24.8%
5 Year-24.7%

ROE%

1 Year1.1%
3 Year10.83%
5 Year8.44%

ROCE %

1 Year2.77%
3 Year11.45%
5 Year9.29%

Debt/Equity

0.1884

Price to Cash Flow

-346.39

Interest Cover Ratio

1.756

CFO/PAT (5 Yr. Avg.)

0.29228769957036

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 60.64 0.00
Dec 2024 60.64 0.00
Sep 2024 60.64 0.00
Jun 2024 60.64 0.00
Mar 2024 60.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 74.837 days.
  • Company has a healthy liquidity position with current ratio of 3.9931.
  • The company has a high promoter holding of 60.64%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 44.1451080008243.

 Limitations

  • The company has shown a poor profit growth of -24.796879906375% for the Past 3 years.
  • The company has shown a poor revenue growth of 1.59951711415043% for the Past 3 years.
  • Company has negative cash flow from operations of -123.2.
  • The company is trading at a high PE of 70.04.
  • The company is trading at a high EV/EBITDA of 108.339.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 532.6 510.6 525.4 562.8 643.8
Total Expenditure 480.4 465.7 487.8 531.5 581.8
Operating Profit 52.2 44.9 37.6 31.3 62
Other Income 38.9 41.9 73.5 64.2 62.7
Interest 39.5 55.2 59.7 65.3 56.7
Depreciation 29.8 30.5 30.5 33.8 33
Exceptional Items 0 0 0 607.5 0
Profit Before Tax 21.8 1.1 20.9 603.9 35
Tax 7.8 0.2 17.7 19.9 13.8
Profit After Tax 14 0.9 3.2 584 21.2
Adjusted EPS (Rs) 0.12 0.01 0.03 4.86 0.18

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 1988.4 2028.4 1738.2 1992.9 2127.3
Total Expenditure 1706.5 1717.2 1677.1 1972.1 1911.6
Operating Profit 281.9 311.2 61.1 20.8 215.7
Other Income 205.8 151.5 187.2 274.1 240
Interest 1.2 0.4 0.4 69.6 198.8
Depreciation 98 103.5 108.2 116.9 121.1
Exceptional Items 159.7 0 0 2862.8 14.5
Profit Before Tax 548.2 358.8 139.7 2971.2 150.3
Tax 111.9 78.3 53.6 122.8 31
Net Profit 440.9 280.5 86.1 2848.4 119.3
Adjusted EPS (Rs.) 3.64 2.34 0.72 23.72 0.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 600 600 600.3 600.3 600.3
Total Reserves 6937.3 7307.1 7492.6 10315.7 10312
Borrowings 0.7 0 75.9 1297.7 2040.8
Other N/C liabilities -134.7 -30 -10.7 95.4 116.5
Current liabilities 728 550.2 590.9 698 691.2
Total Liabilities 8131.3 8427.3 8749 13007.1 13760.8
Assets
Net Block 720.7 728.6 804.7 899.4 900.4
Capital WIP 151.9 164.6 270.3 328.9 545
Intangible WIP 0 14.6 14.6 14.6 14.6
Investments 4814 5073.4 5017.8 8949.8 9255.6
Loans & Advances 280.9 150.5 154.2 159 204.1
Other N/C Assets 80.1 126.3 85.2 89.4 81.1
Current Assets 2083.7 2169.3 2402.2 2566 2760
Total Assets 8131.3 8427.3 8749 13007.1 13760.8
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 559.9 358.8 139.7 2971.2 150.3
Adjustment -68.1 117.8 108.3 -2726.9 112.3
Changes in Assets & Liabilities -14 156 -172 16.1 -358.3
Tax Paid -90.7 -61.3 -28.4 -41.1 -27.5
Operating Cash Flow 387.1 571.3 47.6 219.3 -123.2
Investing Cash Flow -188.9 -720.6 -302.1 -1173.1 -294.7
Financing Cash Flow -128.9 27.8 112 1039.4 343.6
Net Cash Flow 69.3 -121.5 -142.5 85.6 -74.3

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 60.64 60.64 60.64 60.64 60.64
dev mazumdar 0.08 0.08 0.08 0.08 0.08
glentec international 19.76 19.76 19.76 19.76 19.76
kiran mazumdar shaw 40.36 40.36 40.36 40.36 40.36
ravi rasendra mazumdar 0.44 0.44 0.44 0.44 0.44
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 39.36 39.36 39.36 39.36 39.36
arun suresh chandavarkar 1.10 1.10 1.10 1.10 1.10
beneficial holdings under... 0.46 0.46 0.46 0.46 0.46
investor education and pr... 0.01 0.01 - 0.01 0.01
kotak equity opportunitie... - 1.55 - - 1.28
lici ulip-growth fund - - 5.09 - 5.34
nippon life india trustee... - - - - 1.25
sbi healthcare opportunit... - - - 3.17 3.43
kotak balanced advantage ... - - - 1.49 -
life insurance corporatio... - - - 5.34 -
investor education and pr... - - 0.01 - -
kotak esg opportunities f... - - 1.46 - -
sbi arbitrage opportuniti... - - 2.43 - -
lici child fortune plus g... 4.41 4.94 - - -
sbi contra fund 2.74 2.72 - - -
quant mutual fund - quant... 1.24 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit INDIA RATINGS
Credit CRISIL
Credit FITCH
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit FITCH
Credit CRISIL
Credit ICRA
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit ICRA
Credit ICRA
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit ICRA
TYPE AGENCY ACTION
Research Motilal Oswal
Research HDFC Securities
Research Motilal Oswal
Research Nirmal Bang
Research Hem Securities
Research ICICI Securities Limited
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q4FY24
Concall Q4FY22
Concall Q4FY20
Concall Q3FY25
Concall Q3FY24
Concall Q3FY21
Concall Q3 FY20
Concall Q2FY24
Concall Q2FY23
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY24
Concall Q1FY21
Concall Q1FY20
TYPE QUARTER ACTION
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY22
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY22
Presentation Q3FY21
Presentation Q3 FY20
Presentation Q2FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY23
Presentation Q1FY22
Presentation Q1FY21
Presentation Q1FY20

Company News

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time. Biocon stock price today is Rs 355.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Biocon cash from the operating activity was Rs -123.2 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.1884 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was -95.8116 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 10.1396135946975 % which is a bad sign for profitability.
     
  • ROE: Biocon have a poor ROE of 1.1027 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Biocon is Rs 355.4. One can use valuation calculators of ticker to know if Biocon share price is undervalued or overvalued.
Last Updated on:
Brief about Biocon
X